Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab Dose Escalation in Stem Cell Transplant
NCT00118352Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Mar 2005
- Primary completion
- Jul 2010
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab in hematologic malignancy, sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Incidence of Grade III-IV Acute GVHD at 100 days. Started Mar 2005; status: completed.
02
Drugs
alemtuzumab
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT00118352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00118352.